Novan, Inc.

Based in the US, Novan, Inc. is a biotechnology company that develops innovative therapies targeting unmet medical needs in dermatology, particularly focusing on skin conditions affecting children. Novan, Inc. specializes in biotechnology with a focus on developing treatments for dermatological conditions.

Founded in 2006, the company is headquartered in Durham, North Carolina, US. The company has undergone significant funding activity, raising a total of USD 38. 00 mn in its latest round, a Private Placement/Follow on in September 2016, and has completed 11 deals to date. The CEO is Donald Hamilton, alongside Paula Stafford.

Novan, Inc. offers therapeutic products through its Pelthos Therapeutics division, which focuses on a nitric oxide-based technology platform designed to treat various skin conditions. Their primary offerings include treatments for Molluscum Contagiosum, a contagious skin infection predominantly affecting children, aiming to improve patient outcomes and healthcare provider access. In the most recent fiscal year of 2022, Novan, Inc.

reported a revenue of USD 23. 68 mn with an EBITDA of USD -31. 45 mn, reflecting the company's financial performance amid their ongoing product commercialization efforts. Moving forward, Novan, Inc.

plans to expand its product line with new therapies aimed at dermatological conditions, anticipated to launch in the next 12-24 months. The company is also targeting expansion into international markets, specifically in Europe and Asia, by 2024. The recent funding will be utilized to enhance research and development efforts in their innovative therapeutic pipeline, as well as to facilitate the market entry of their flagship products.